Acute Myeloid Leukaemia (AML) Archives

FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML

Presented By

Dr Wei-Ying Jen, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:20

CD40/CD47 inhibitor shows promise in high-risk MDS and AML

Presented By

Prof. Amer Zeidan, Yale University, CT, USA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?

Presented By

Dr Anne Sophie Kubasch, University of Leipzig, Germany

Trial

Phase 2, RELAZA2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can WGTS replace standard-of-care diagnostics in AML?

Presented By

Dr Anna Staffas, University of Gothenburg, Sweden

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

FLT3-ITD-specific MRD assessment useful for clinical management of AML

Presented By

Prof. Alexander Perl, University of Pennsylvania, PA, USA

Trial

Phase 3, QuANTUM-First

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:05

MRD status rather than FLT3-ITD co-mutation is linked to the benefit of CR1-allo in NPM1-mutated AML

Presented By

Dr Jad Othman, Royal North Shore Hospital, Australia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Promising results for quizartinib, venetoclax, and decitabine in FLT3-ITD mutated AML

Presented By

Dr Musa Yilmaz, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

QuANTUM-First: Updated results on quizartinib in AML with FLT3-ITD

Presented By

Dr Richard Schlenk, University of Heidelberg, Germany

Trial

Phase 3, QuANTUM-First

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:54

Promising data for ziftomenib in relapsed/refractory NPM1-mutated AML

Presented By

Dr Amir Fathi, Massachusetts General Hospital, Massachusetts, USA

Trial

Phase 1/2, KOMET-001

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:51

MRD-positive patients with FLT3-ITD AML may benefit from post-transplant gilteritinib

Presented By

Dr Mark Levis, Johns Hopkins Hospital, Maryland, USA

Trial

MORPHO

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:45

QUIWI: First results suggest a clinical benefit of quizartinib in AML

Presented By

Dr Pau Montesinos, University of Valencia, Spain

Trial

Phase 2, QUIWI

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:38

Next-generation cell therapies for cancer: CAR-NK cells

Presented By

Dr Katy Rezvani, MD Anderson Cancer Center, TX, USA

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:20

Quizartinib plus chemotherapy improves OS in patients with AML undergoing ASCT

Presented By

Prof. Radovan Vrhovac, University Hospital Centre Zagreb, Croatia

Trial

Phase 3, QuANTUM-First

Conference

EMBT 2023

Type

Peer-reviewed article

14 June 2023 20:07

Tacrolimus versus cyclosporin A in AML

Presented By

Dr Gesine Bug, Goethe University Frankfurt, Germany

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:48

Promising novel target identified for AML

Presented By

Prof. Edmund Waller, Emory University, GA, USA

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:42

Excellent results for triplet regimen in FLT3-mutated AML

Presented By

Prof. Nicholas Short, University of Texas, TX, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:25

MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML

Presented By

Mr Jad Othman, Guy’s and St Thomas’ NHS Foundation Trust, UK

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:20

Promising results for triplet therapy with magrolimab in AML

Presented By

Prof. Naval Daver, Anderson Cancer Center, TX, USA

Trial

Phase 3, ENHANCE-3

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:17

Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML?

Presented By

Prof. Matthias Stelljes, University of Muenster, Germany

Trial

Phase 3, EATL3-ASAP

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:13

Pan-clonal score predicts first-line treatment response in AML

Presented By

Dr Yannik Severin, ETH Zurich, Switzerland

Conference

EHA 2022

Type

News article

1 July 2022 11:54

Quizartinib prolongs survival of newly diagnosed FLT3-ITD-mutated AML

Presented By

Dr Harry Erba, Duke Cancer Institute, NC, USA

Trial

Phase 3, QuANTUM-First

Conference

EHA 2022

Type

News article

1 July 2022 11:52

No survival benefit of CPX-351 over FLAG-Ida in AML patients with adverse cytogenetics

Presented By

Prof. Nigel Russell, Guy's and St Thomas' NHS Foundation Trust, UK

Trial

Phase 3, AML19

Conference

EHA 2022

Type

News article

1 July 2022 11:49

AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML

Presented By

Dr Hartmut Döhner, Universitätsklinikum Ulm, Germany

Trial

Phase 2, AMLSG 16-10

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:53

Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients

Presented By

Dr Justin Grenet, Weill Cornell Medical Center, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:51

Promising frontline triplet regimen for TP53-mutated AML

Presented By

Dr Naval Daver, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:49

Encouraging results of novel triplet combination for AML

Presented By

Dr Patrick Reville, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:48

Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen

Presented By

Dr Musa Yilmaz, MD Anderson Cancer Center, TX, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:46

Benefits of eprenetapopt plus azacitidine for TP53-mutant MDS and oligoblastic AML

Presented By

Dr David Sallman, H. Lee Moffitt Cancer Center, FL, USA

Trial

Phase 2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:44

Mechanisms behind TP53 mutations revealed in myeloproliferative neoplasms

Presented By

Dr Alba Rodriguez-Meira, University of Oxford, UK

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:51

ASH 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASH 2021

4 January 2022 08:00

Olutasidenib demonstrates efficacy in patients with relapsed/refractory IDH1 mutant AML

Presented By

Dr Stéphane de Botton , Institute Gustave Roussy, France

Trial

Phase 2, 2102M 101

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:20

Oral azacitidine improves overall survival in patients with acute myeloid leukaemia

Presented By

Prof. Hartmut Döhner, Universitätsklinikum Ulm, Germany

Trial

Phase 2, QUAZAR AML-001

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:59

Reduced-intensity conditioning ASCT is effective in older patients with AML

Presented By

Prof. Nigel Russell, Guy's Hospital, UK

Trial

AML16; AML18

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:55

More complicated course of COVID-19 in leukaemia patients

Presented By

Dr Susanne Ghandili, University Medical Center Hamburg-Eppendorf, Germany

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:34

Prognostic validity of AML composite model in predicting mortality

Presented By

Dr Shannon Murphy, Dalhousie University, Canada

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:21

Venetoclax plus hypomethylating agents in favourable-risk AML

Presented By

Dr Shukaib Arslan, City Of Hope Helford Clinical Research Hospital, California, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:19

Encouraging clinical activity of decitabine plus ipilimumab in R/R or secondary MDS/AML

Presented By

Ms Jacqueline S. Garcia, Dana-Farber Institute, Massachusetts, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:18

AML patients with specific mutations are unlikely to achieve MRD

Presented By

Dr Maximilian Stahl, Memorial Sloan Kettering Cancer Center, New York, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:15

Comparable outcomes with gilteritinib or quizartinib in R/R AML

Presented By

Dr Alexander Perl, University of Pennsylvania, USA

Trial

Phase 3, QuANTUM-R

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:14

First-in-class macrophage immune checkpoint inhibitor in AML

Presented By

Dr David Sallman, H. Lee Moffitt Cancer Center and Research Institute, Florida, USA

Trial

Phase 1

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:11

Bispecific DART® as salvage therapy for primary induction failure and early relapse

Presented By

Dr Ibrahim Aldoss, City of Hope Medical Center, California, USA

Trial

Phase 1/2

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:09

Gilteritinib in R/R AML patients priorly treated with midostaurin or sorafenib

Presented By

Dr Alexander Perl, University of Pennsylvania, USA

Trial

CHRYSALIS, ADMIRAL

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:07

Addition of venetoclax provides an effective, lower-intensity regimen

Presented By

Dr Tapan Kadia, MD Anderson Cancer Center, Texas, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:05

VIALE-A: newly diagnosed chemo-ineligible AML

Presented By

Dr Courtney Di Nardo, MD Anderson Cancer Centre, USA

Trial

Phase 3, VIALE-A

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 13:25

OS benefit in VIALE-C trial

Presented By

Prof. Andrew Wei, Monash University, Australia

Trial

Phase 3, VIALE-C

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 13:22

DEC10-VEN superior to intensive chemotherapy in high-risk AML

Presented By

Dr Abhishek Maiti, University of Texas MD Anderson Cancer Centre, USA

Trial

Phase 2

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 13:18

Magrolimab plus azacitidine: good ORR in MDS/AML

Presented By

Prof. Naval Draver, University of Texas MD Anderson Cancer Centre, USA

Trial

Phase 1

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 13:14

Better outcomes adding enasidenib to azacitidine in mIDH2-AML

Presented By

Dr Courtney Di Nardo, MD Anderson Cancer Centre, USA

Trial

Phase 2, AG-221-AML-005

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:55

Socioeconomic disparities and survival in paediatric AML

Presented By

Dr Lena Winestone, UCSF Benioff Children’s Hospital, USA

Trial

Phase 3, AAML0531 and AAML1031

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 23:55

Oral azacitidine improves overall survival in patients with AML in remission

Presented By

Dr Andrew Wei, Alfred Hospital, Australia

Trial

Phase 3, QUAZAR AML-001

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 21:39

Mild renal impairment in African Americans does not affect OS in AML

Presented By

Dr Abby Statler, Cleveland Clinic, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 19:10

Anti-CD70 is safe with hypomethylating agents in AML

Presented By

Prof. Adrian Ochsenbein, Bern University Hospital, Switzerland

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 17:01

MRD assessment to guide pre-emptive treatment decisions

Presented By

Prof. Uwe Platzbecker, University Hospital Carl Gustav Carus, Germany

Trial

Phase 2, RELAZA2

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 16:04

Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance

Presented By

Prof. Gill Singh, University of Hong Kong, China

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 14:13

Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT

Presented By

Dr Xiaowen Tang; Dr James Foran

Trial

Phase 2, ECOG-ACRIN E2906

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 13:16

Residual disease in AML patients prior to stem cell transplant increases relapse risk

Presented By

Dr Christopher Hourigan, NIH, USA

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 23:05

Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML

Presented By

Dr Alexander Perl, University of Pennsylvania, USA

Trial

Phase 3, ADMIRAL

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 22:14

Initial data on AMV564 in patients with relapsed/refractory AML

Presented By

Prof. Gail Roboz, Weill Cornell Medicine, USA

Trial

Phase 1, AMV564-101

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 21:18

Overcoming the “don’t eat me” signal in AML and MDS

Presented By

Dr David Sallman, Moffitt Cancer Center, USA

Trial

5F9005

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 20:20

Guadecitabine vs treatment of choice in AML

Presented By

Prof. Pierre Fenaux, Hôpital Saint-Louis, France

Trial

Phase 3, ASTRAL-1

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 09:25